| 2017-GHOS-67971 | |
| According to the National Cancer Institute, approximately 40 percent of people will be diagnosed with cancer in their lifetime and worldwide number of diagnostics are predicted to increase nearly 50 percent by 2030. Nearly 2 percent of all men and 1.5 percent of all women are killed each year by cancer. Cancer is simply described as continuous and uncontrolled division of cells leading to tumors. With the increase in cancer cases worldwide and the lack of a consistent treatment, new development are still needed in the field. Researchers at Purdue University have synthesized a number of natural products that inhibit cell splicing. These herboxidiene derivatives inhibit cell division through its interactions with the proteins responsible for pre-mRNA splicing. This technology shows potential for use in a variety of select human cancers with increased functionality and consistent stability and potency. Advantages: -Stable and potent -Appropriate drug functionalities for conjugates Potential Applications: -Pharmaceuticals -Anticancer, chemotherapy drugs |
|
|
|
|
Jan 24, 2020
NATL-Patent
United States
(None)
(None)
Jul 26, 2018
PCT-Patent
WO
(None)
(None)
Jul 26, 2017
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |